TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

As Donald Trump secures the 2024 U.S. presidency, prominent Indian-Americans, including Sundar Pichai, Satya Nadella, and Nikki Haley, share their congratulations and optimism for the future. These ...

Strive Enterprises, a financial services company co-founded by former Republican presidential candidate Vivek Ramaswamy, has announced plans to move its headquarters to Dallas.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Strive Enterprises, co-founded by the former Republican presidential candidate, is also launching a wealth management ...

Beyond Air, Inc. (NASDAQ: XAIR) is a global leader in medical technology focused on developing transformative treatments for lung diseases. The company's LungFit ® platform is a revolutionary NO ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio. With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof) ...

Roivant Sciences ( (ROIV) ) has shared an update. Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio ...

A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences (NASDAQ:ROIV), reported the exercise of a large sell of company stock options.

A large exercise of company stock options by Eric Venker, President & COO at Roivant Sciences (NASDAQ:ROIV) was disclosed in a new SEC filing on October 23, as part of an insider exercise.